Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 1, 2012, Pages 184-197

  Pujols, Laura ^a   Fernández Bertolín, Laura ^a   Fuentes Prado, Mireya ^a   Alobid, Isam ^a,b   Roca Ferrer, Jordi ^a   Agell, Neus ^c   Mullol, Joaquim ^a,b   Picado, César ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; COLLAGEN; CYTOKINE; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MG 262; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME INHIBITOR; PROTEIN C JUN; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA REPLICATION; DRUG EFFICACY; ENDOSCOPIC SINUS SURGERY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NOSE MUCOSA; NOSE POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ADULT; BORONIC ACIDS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CYTOKINES; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS; PROTEASOME INHIBITORS;

EID: 84866315635     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190710     Document Type: Article

References (54)

1. Adams J (2003) The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 (Suppl 1):3-9.
2. Bachert C, Van Bruaene N, Toskala E, Zhang N, Olze H, Scadding G, Van Drunen CM, Mullol J, Cardell L, Gevaert P, et al. (2009) Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis-a GALEN study. Allergy 64:520-533.
3. Barnes PJ and Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071. (Pubitemid 27163860)
4. Burgess JK (2009) The role of the extracellular matrix and specific growth factors in the regulation of inflammation and remodelling in asthma. Pharmacol Ther 122:19-29.
5. Carmignac V, Quéré R, and Durbeej M (2011) Proteasome inhibition improves the muscle of laminin α2 chain-deficient mice. Hum Mol Genet 20:541-552.
6. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, et al. (2006) Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5:665-675.
7. Cuschieri J, Gourlay D, Garcia I, Jelacic S, and Maier RV (2004) Implications of proteasome inhibition: an enhanced macrophage phenotype. Cell Immunol 227:140-147. (Pubitemid 38595386)
8. Domingo-Domènech J, Pippa R, Tápia M, Gascón P, Bachs O, and Bosch M (2008) Inactivation of NF-κB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112:53-62.
9. Elliott PJ, Pien CS, McCormack TA, Chapman ID, and Adams J (1999) Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 104:294-300. (Pubitemid 29420423)
10. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495-516.
11. Fineschi S, Bongiovanni M, Donati Y, Djaafar S, Naso F, Goffin L, Argiroffo CB, Pache JC, Dayer JM, Ferrari-Lacraz S, et al. (2008) In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 39:458-465.
12. Fineschi S, Reith W, Guerne PA, Dayer JM, and Chizzolini C (2006) Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 20:562-564. (Pubitemid 46671250)
13. Fokkens W, Lund V, Mullol J, and European Position Paper on Rhinosinusitis and Nasal Polyps group (2007) European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 20:1-136.
14. Gerber A, Heimburg A, Reisenauer A, Wille A, Welte T, and Bühling F (2004) Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells. Eur Respir J 24:40-48. (Pubitemid 39029067)
15. Ghosh AK (2002) Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 227:301-314.
16. Ghosh AK, Bhattacharyya S, and Varga J (2004) The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279:47455-47463. (Pubitemid 39540888)
17. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, and Varga J (2009) Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23:2968-2977.
18. Goffin L, Seguin-Estévez Q, Alvarez M, Reith W, and Chizzolini C (2010) Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther 12:R73.
19. Goldbaum O, Vollmer G, and Richter-Landsberg C (2006) Proteasome inhibition by MG-132 induces apoptotic cell death and mitochondrial dysfunction in cultured rat brain oligodendrocytes but not in astrocytes. Glia 53:891-901.
20. 1-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol 210:167-176.
21. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, and Stacey DW (2005) Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 24:2599-2612. (Pubitemid 40593088)
22. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, et al. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534. (Pubitemid 36182530)
23. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076. (Pubitemid 32691956)
24. Hipp MS, Urbich C, Mayer P, Wischhusen J, Weller M, Kracht M, and Spyridopoulos I (2002) Proteasome inhibition leads to NF-κB-independent IL-8 transactivation in human endothelial cells through induction of AP-1. Eur J Immunol 32:2208-2217. (Pubitemid 34965883)
25. Kawakami A, Nakashima T, Sakai H, Hida A, Urayama S, Yamasaki S, Nakamura H, Ida H, Ichinose Y, Aoyagi T, et al. (1999) Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum 42:2440-2448. (Pubitemid 30333425)
26. Le Bellego F, Perera H, Plante S, Chakir J, Hamid Q, and Ludwig MS (2009) Mechanical strain increases cytokine and chemokine production in bronchial fibroblasts from asthmatic patients. Allergy 64:32-39.
27. 2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154.
28. Ling YH, Liebes L, Zou Y, and Perez-Soler R (2003b) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278:33714-33723. (Pubitemid 37553204)
29. Liu Y, Shepherd EG, and Nelin LD (2007) MAPK phosphatases-regulating the immune response. Nat Rev Immunol 7:202-212.
30. Ludwig A, Fechner M, Wilck N, Meiners S, Grimbo N, Baumann G, Stangl V, and Stangl K (2009) Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system. J Mol Med 87:793-802.
31. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C, Godes M, Mrozikiewicz A, Baumann G, and Stangl K (2004) Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 44:471-477. (Pubitemid 39281498)
32. Meiners S, Ludwig A, Stangl V, and Stangl K (2008) Proteasome inhibitors: poisons and remedies. Med Res Rev 28:309-327. (Pubitemid 351281191)
33. Meyer JE, Berner I, Teran LM, Bartels J, Sticherling M, Schröder JM, and Maune S (1998) RANTES production by cytokine-stimulated nasal fibroblasts: its inhibition by glucocorticoids. Int Arch Allergy Immunol 117:60-67. (Pubitemid 28430173)
34. Moutzouris JP, Che W, Ramsay EE, Manetsch M, Alkhouri H, Bjorkman AM, Schuster F, Ge Q, and Ammit AJ (2010) Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion. Biochim Biophys Acta 1803:416-423.
35. Mutlu GM, Budinger GR, Wu M, Lam AP, Zirk A, Rivera S, Urich D, Chiarella SE, Go LH, Ghosh AK, et al. (2012) Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1 signalling. Thorax 67:139-146.
36. Myllyharju J and Kivirikko KI (2004) Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 20:33-43. (Pubitemid 38032818)
37. Nacu N, Luzina IG, Highsmith K, Lockatell V, Pochetuhen K, Cooper ZA, Gillmeister MP, Todd NW, and Atamas SP (2008) Macrophages produce TGF-β-induced (β-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J Immunol 180:5036-5044.
38. Nonaka M, Pawankar R, Saji F, and Yagi T (1999) Distinct expression of RANTES and GM-CSF by lipopolysaccharide in human nasal fibroblasts but not in other airway fibroblasts. Int Arch Allergy Immunol 119:314-321. (Pubitemid 29401701)
39. Ortiz-Lazareno PC, Hernandez-Flores G, Dominguez-Rodriguez JR, Lerma-Diaz JM, Jave-Suarez LF, Aguilar-Lemarroy A, Gomez-Contreras PC, Scott-Algara D, and Bravo-Cuellar A (2008) MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-κB and activator protein-1. Immunology 124:534-541. (Pubitemid 351962549)
40. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, et al. (1998) Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95:15671-15676. (Pubitemid 29018758)
41. Pawliczak R, Lewandowska-Polak A, and Kowalski ML (2005) Pathogenesis of nasal polyps: an update. Curr Allergy Asthma Rep 5:463-471. (Pubitemid 41683970)
42. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
43. Poznic M (2009) Retinoblastoma protein: a central processing unit. J Biosci 34:305-312.
44. Pujols L, Fuentes-Prado M, Fernández-Bertolín L, Alobid I, Roca-Ferrer J, Mullol J, and Picado C (2011) Lower sensitivity of nasal polyp fibroblasts to glucocorticoid anti-proliferative effects. Respir Med 105:218-225.
45. Schmidt N, Gonzalez E, Visekruna A, Kühl AA, Loddenkemper C, Mollenkopf H, Kaufmann SH, Steinhoff U, and Joeris T (2010) Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59:896-906.
46. 1-phase progression. Genes Dev 13:1501-1512.
47. Silbiger S, Lei J, and Neugarten J (1999) Estradiol suppresses type I collagen synthesis in mesangial cells via activation of activator protein-1. Kidney Int 55:1268-1276. (Pubitemid 29157124)
48. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, and Orlowski RZ (2004) Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66:1478-1490. (Pubitemid 39564774)
49. Small GW, Shi YY, Higgins LS, and Orlowski RZ (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67:4459-4466. (Pubitemid 46815096)
50. Xing Z, Jordana M, Braciak T, Ohtoshi T, and Gauldie J (1993) Lipopolysaccharide induces expression of granulocyte/macrophage colony-stimulating factor, interleukin-8, and interleukin-6 in human nasal, but not lung, fibroblasts: evidence for heterogeneity within the respiratory tract. Am J Respir Cell Mol Biol 9:255-263.
51. Wang J and Maldonado MA (2006) The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3:255-261.
52. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, and Taguchi H (2004) Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95:176-180. (Pubitemid 38404320)
53. Yannaki E, Papadopoulou A, Athanasiou E, Kaloyannidis P, Paraskeva A, Bougiouklis D, Palladas P, Yiangou M, and Anagnostopoulos A (2010) The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adju-vant- induced arthritis in rats. Arthritis Rheum 62:3277-3288.
54. You BR and Park WH (2011) Proteasome inhibition by MG132 induces growth inhibition and death of human pulmonary fibroblast cells in a caspase-independent manner. Oncol Rep 25:1705-1712.